Tag Archives: GSK4427296

GSK Deprioritizes Cell Therapy Franchise; GSK’s Q3 2022 Earnings Summary

On Wednesday, November 2, GSK held its Q3 2022 earnings call (press release / presentation), highlighting the removal of three clinical TCR-T programs from its pipeline. Below, Celltelligence provides insights on GSK’s pipeline update, while discussing the company’s future in cell therapy.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.